Understanding how to better treat malaria in children with and without HIV
Delineating host, parasite and pharmacologic factors impacting the treatment of malaria in children with and without HIV
This study is looking at how well different lengths of malaria treatment work for children, especially those who also have HIV, to see if a longer 5-day treatment helps them get better and stay healthy longer.
Quick facts
| Grant type | R21 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Yale University NIH-funded |
| Lab location | 1 site (New Haven, United States) |
| Project ID | NIH-10700089 on NIH RePORTER |
What this research studies
This research investigates the effectiveness of different treatment regimens for malaria in children, particularly focusing on those who are also living with HIV. The study compares a standard 3-day treatment with an extended 5-day treatment of artemether-lumefantrine, a common antimalarial drug, to see if longer treatment improves drug levels and reduces the risk of recurrent infections. By examining the safety and pharmacokinetics of these treatments in a high malaria transmission area in Uganda, the research aims to enhance treatment outcomes for vulnerable populations.
Who could benefit from this research
Good fit: Ideal candidates for this research include children aged 0-11 years living in sub-Saharan Africa, especially those diagnosed with malaria and HIV.
Not a fit: Patients who are not children or those without malaria or HIV may not receive any benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to improved malaria treatment protocols for children, particularly those co-infected with HIV, potentially reducing morbidity and mortality rates.
How similar studies have performed: Previous research has shown that extended treatment regimens can improve drug efficacy in similar populations, suggesting a promising avenue for this approach.
Where this research is happening
New Haven, United States
- Yale University — New Haven, United States (Active)
Researchers
- Principal investigator: Parikh, Sunil — Yale University
- Study coordinator: Parikh, Sunil
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.